IP Library Granted Patent US 12697381
Granted Patent B2
US 12697381 · App. 18/249,431 · Granted Aug 4, 2026

Baculovirus expression vector

Inventor: Erwin Van Den Born (Boxmeer, NL)
Assignee: Intervet, Inc.
A61K39/135C12N15/866C12N2710/14041C12N2780/00034C12N2799/026
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12697381
App. No.
18/249,431
Granted
Aug 4, 2026
Kind
B2
Abstract

The invention concerns a baculovirus expression vector for recombinantly expressing a Foot-and-mouth disease virus (FMDV) capsid precursor protein under control of a promoter, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein, wherein the ATG start codon of an open reading frame encoding the FMDV capsid precursor protein is preceded at position −4 to −1 by the nucleic acid sequence 5′-AAAT-3′. The invention further relates to a host cell comprising the baculovirus expression vector, a method of producing FMDV virus-like particles (VLPs), and a method of producing a vaccine.

Claims (19)

1 . A baculovirus expression vector for recombinantly expressing a Foot and mouth disease virus (FMDV) capsid precursor protein, the expression vector comprising a nucleic acid sequence encoding the FMDV capsid precursor protein under the control of a promoter, wherein the ATG start codon of an open reading frame encoding the FMDV capsid precursor protein is preceded at position −4 to −1 by the nucleic acid sequence 5′-AAAT-3′ and wherein the FMDV is of the Asia1 or SAT2 serotype.

2 . The baculovirus expression vector according to claim 1 , the vector further comprising one or more restriction sites for cleavage by one or more restriction enzymes between the nucleic acid sequence at position −4 to −1 of 5′-AAAT-3′ and the promoter.

3 . The baculovirus expression vector according to claim 1 , having the nucleic acid sequence 5′-GGTAACCAAAT-3′ (SEQ ID NO. 1) at position −11 to −1.

4 . The baculovirus expression vector according to claim 1 , wherein expression of the FMDV capsid precursor protein is achieved under the control of the baculovirus polyhedrin promoter (polh) or p10 promoter.

5 . The baculovirus expression vector according to claim 1 , wherein the capsid precursor protein comprises the capsid precursor P1.

6 . The baculovirus expression vector according to claim 1 , the vector further comprising a nucleic acid sequence encoding a protease capable of cleaving the capsid precursor protein into one or more capsid proteins.

7 . The baculovirus expression vector according to claim 6 , wherein the capsid precursor protein comprises the capsid precursor P1 and the peptide 2A and the protease is 3C.

8 . A host cell comprising the baculovirus expression vector according to claim 1 .

9 . The host cell according to claim 8 , which is an insect cell.

10 . A method of producing FMDV capsid precursor protein, the method comprising the steps of:

(i) infecting a host cell with the baculovirus expression vector according to claim 1 , and

(ii) harvesting FMDV capsid precursor protein produced by the host cell.

11 . A method of producing FMDV virus-like particles (VLPs), the method comprising the steps of:

(i) infecting a host cell with the baculovirus expression vector according to claim 6 , and

(ii) harvesting FMDV VLPs produced by the host cell.

12 . A method of producing a vaccine, which comprises the steps of:

(i) producing FMDV virus-like particles (VLPs) by the method according to claim 11 and

(ii) incorporating the FMDV VLPs into a vaccine by addition of a pharmaceutically acceptable carrier.

13 . A method of protecting a subject against an infection with FMDV, which comprises the step of expressing an FMDV capsid precursor protein from the baculovirus expression vector according to claim 1 in a host cell to produce a VLPs, incorporating the VLPs into a vaccine by addition of a pharmaceutically acceptable carrier and administering the vaccine to the subject.